SPOTLIGHT -
The First Footfall: What Apple’s “HealthKit” Announcement Means to Healthcare
Among the many announcements Apple made earlier this month at its annual World Wide Developer’s Conference, one was of particular interest to the healthcare industry.
Sanofi Responds to UK’s Value-Based Assessment Plans
The UK’s National Institute for Health and Care Excellence (NICE) set out their proposals for value-based assessment (VBA) in March 2014.
Q&A: Nathan Tinker, New York Biotechnology Association
While at the 2014 New York BIO Conference (NYBIO), Applied Clinical Trials‘ Moe Alsumidaie spoke to Nathan Tinker, Executive Director at the New York Biotechnology Association.
Physicians Won’t Change Their Practices Without Worthwhile Incentives
There is more collaboration than ever between payers and providers in the drive to provide high-quality.
EU Steps Up Manufacturing Inspection Efforts
One of EMA’s key objectives this year is improvements in dealing with the “causes and impact of shortages of human medicines caused by GMP non-compliance and quality defects”.
EU Blocks Further Limits on Human Embryo Research, Backlash Hits
A European bid to impose additional limits on research involving human embryos has been defeated.
How We Fall into Clinical Trial Metrics Malpractice
Effective clinical trial management depends on accurate and unbiased performance measurement.
FDA Targets Online Pharmacies
FDA, in partnership with other federal and international agencies, has taken action against websites that sell potentially dangerous, unapproved prescription drugs to US consumers.
Obamacare's "Unacceptable" Rx Copays
We are now approaching the six month point in the implementation of the new Obamacare program. It’s senseless to go into the good, bad and ugly of this new program.
Fine-Tuning Your Multichannel Marketing Strategy
In today’s pharmaceutical industry, it seems there are nearly as many communication channels as there are instruments in the Philharmonic.
Digital Technology: A Double-Edged Sword
Technology offers the promise of engaging patients on a level never seen before.
What MNCs Can Learn from Generics Companies
In the last three decades, MNCs have contributed greatly to the transfer of knowledge to generic companies in areas such as technology,
Improving Operational Quality through Customer Insight
Every day, your competitors are doing everything within their power to steal your customers.
UK: Patient Group Sets Out Orphan Drug Charter
There has been a lot of concern about the decision to give the National Institute for Health and Care Excellence (NICE) the responsibility to look at “highly specialized technologies” (HSTs, or orphan drugs to you and me).
Global Price Management Key to Boosting Margins
Global price management will lead the fight-back on margins, writes Arnaud Grunwald.
The European Medicine Agency’s Transparency Dilemma
The European Medicines Agency thought it might at last be back on the road to salvation when Guido Rasi swept into town in 2011 and started ordering greater transparency in the agency’s operations.
The Future of Cancer Care?
Human behavior may be the most significant variable in the future of cancer care in two sense.
The British Medical Journal's Statin 'Apology'
For any Brit involved in medical publishing, the British Medical Journal (BMJ) is the Holy Grail.
The CMO Industry: Stuck in Neutral
PharmSource recently completed an analysis of the dose CMO industry’s share of new FDA approvals.
How BMS is Doing RBM (Risk-Based Monitoring)
At this year’s Bio IT World Conference, Thomas Verish, Group Director of Data Operations Services at Bristol-Myers Squibb,
Eight Ingredients for a Successful Oncology Drug Development Recipe
In light of the risks and challenges inherent in the development of oncologics.
Strategic Development Partnerships: Preparing for Inevitable Challenges
It’s hardly news that biopharmaceutical companies today face increasing pressure to innovate, produce, improve efficiency and quality.
Antibiotics Discovery: Time for a ‘Manhattan Project’
The innovative pharmaceutical industry is under attack from critics around the world for failing to develop new antibiotics to treat emerging infections.
Merger Mania: When the Music Stops
As expected, the PFE/AZ saga has just begun to play out, and as we listen to the music of mega-mergers once again.
Pfizer–AstraZeneca Implications for the Future of International Pharma
The Pfizer-AstraZeneca courtship raises many fascinating questions about the future shape of the international pharmaceutical industry.
England: Ignoring NICE Guidelines Can Be Unlawful
A CCG had denied funding for oocyte preservation for a woman with Crohn’s disease before she had bone marrow transplant and chemotherapy.
The United Kingdom: Rx for America's Pharma Tax Blues?
The dizzying flurry of press releases from both Pfizer Inc. and AstraZeneca over a possible PFE acquisition of AZN have Rx experts on both sides of the Atlantic buzzing.
European Pharma Must Get Its Data in Order
New data maintenance guidelines have sparked a flurry of activity in Europe.
Pursuing the 'Real' Cost Effectiveness Threshold in England
The Incremental Cost Effectiveness Ratio (ICER) thresholds used by agencies such as the UK’s National Institute for Health and Care Excellence (NICE).
CRO M&As Show No Sign of Slowing Down
With all of the activity in CRO M&As the past three years, it’s slightly amazing that it continues - and that analysts don’t see it slowing down.